Skip to content
Screener

ADMA Biologics ADMA G&A

Discontinued — last reported Q1 '21

G&A at other companies

AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$26.2M+85.4%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$8.1M+54.5%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$21.95M+31.4%
BioLife Solutions logo
BioLife SolutionsBLFS
$10.69M-4.8%

Segments

By segment

See full
ADMA Bio Manufacturing$8.34M-44.2%
Plasma Collection Centers$0—

Other financials

Income statement

See full
Revenue$124.4M+2.0%
Gross profit$86.3M+28.3%
Operating income$52.4M+22.5%
Net income$37.8M+10.5%
EPS (diluted)$0.16+14.3%

Balance sheet

See full
Cash & equivalents$136.0M+50.7%
Total debt$203.9M+1,855%
Total equity$408.2M+2.5%
Total assets$684.2M+22.5%

Cash flow

See full
Operating cash flow$29.5M+39.7%
CapEx$2.3M-6.9%
Free cash flow$27.3M+45.8%

Valuation

See full
Market cap$2.25B-49.1%
Enterprise value$2.32B-46.6%
P/E13.3×-7.9×
P/S4.4×-4.9×

Profitability

See full
Gross margin64.7%+11.7pp
Operating margin43.8%+11.0pp
Net margin33%-11.1pp
FCF margin22.7%+8.9pp

Returns & leverage

See full
Return on equity41.9%-29.3pp
Debt / equity0.5×+0.5×
Current ratio7×+1.6×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: ADMA Biologics’s 10-Q, filed May 12, 2021. Open the filing →

Filed
May 12, 2021, 5:10 PM EDT
Fiscal quarter
Q1 FY2021
Calendar quarter
Q1 2021
Accession
0001193805-21-000657

FAQ

What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.